CVRx Q2 FY26 net loss narrows 4.76% to $14 million; revenue rises 16% to $15.7 million - CVRX News | RalliesCVRx Q2 FY26 net loss narrows 4.76% to $14 million; revenue rises 16% to $15.7 million
C
CVRX• Q2 revenue rises while net loss narrows
- CVRx posted Q2 2026 revenue of $15.7 million, up 16% year over year; net loss narrowed to $14 million, or $0.53 a share.
- Gross margin rose 3 percentage points to 87%; gross profit climbed 20% to $13.7 million.
U.S. growth offsets weaker Europe sales
- U.S. revenue increased 21% to $14.8 million on 466 units; Europe revenue fell 31% to $0.9 million on 40 units.
- Active U.S. implanting centers grew to 258; Humana issued a Medicare Advantage coverage policy for Barostim effective May 1, 2026.
2026 outlook and management comments
- CVRx forecast 2026 revenue of $58 million-$60 million.
- CEO Kevin Hykes cited fewer sales territories, lower productivity, and a prolonged issue with a major payer.
STRW
•
